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ABSTRACT 
 
 
Emily Elizabeth Radford Ryan:  Contraceptive Practices of Advanced Practice Registered 
Nurses in Outpatient Settings 
(Under the direction of SeonAe Yeo) 
 
 Long-acting reversible contraception methods (LARCs) are considered the most 
efficacious methods on the market but despite pervasive endorsements as first-line contraception 
from leading healthcare institutions, LARC use in the US remains low. The literature postulates 
provider behaviors and their individual contraceptive clinical practice may create difficulty 
accessing LARC methods for their patients, specifically when healthcare providers lack the 
knowledge and training required to insert or council patients on choosing LARC methods. This 
project aims to examine whether contraceptive clinical practice (CCP) pattern varies by graduate 
practice program preparation of the provider and explore factors related to routine counseling of 
LARC methods by providers. 
Using a convenience sample of advanced practice registered nurses, identified through a 
data request made to The North Carolina Board of Nursing, and a modified version of the 
National Pregnancy and HIV/STI Prevention Survey, responses from 810 participants were 
analyzed. There were statistically significant differences among the CCP of primary care 
providers as compared to women’s health providers across a variety of measures all of which 
both individually and collectively have the potential to affect the quality of contraceptive 
counseling and services provided.  
 
iv 
While some paradigm shifts in healthcare occur rapidly, it is clear that the adoption of 
LARC methods in the primary care setting has had slower trajectory toward full incorporation. 
Despite that, we remain encouraged by the changes we have seen and the interest expressed by 
participants in learning more about LARC methods.
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 CHAPTER 1 
INTRODUCTION 
Long-acting reversible contraception methods (LARCs) are considered the most 
efficacious methods on the market but utilization among American women remains low, 
estimated at 11.6% compared to 25.9% for the pill and 15.3% for male condoms, while 10% 
used no method at all (Guttmacher Institute, 2016).  In the United States, roughly half of all 
pregnancies each year are unintended; defined as a pregnancy that is either mistimed— where 
the woman did not wish to become pregnant but desires pregnancy in the future— or unwanted 
at the time of conception (Guttmacher Institute, 2015).  Unintended pregnancies are divided into 
mistimed (27% of pregnancies) and unwanted (18% of pregnancies) (Guttmacher Institute, 
2016). Mistimed pregnancies are those that are unplanned but occur in women reporting a desire 
to become pregnant in the future (Guttmacher Institute, 2016).  Unwanted pregnancies are 
unplanned pregnancies that occur in women who report neither desiring pregnancy now or at any 
point in the future (Guttmacher Institute, 2016).   Consequences of unintended pregnancies range 
from the increased risk of delaying prenatal care and related poor outcomes for mother and child, 
to economic concerns where unplanned pregnancies are known to cost federal and state 
taxpayers between $9.6 and $12.6 billion annually  (Guttmacher Institute, 2015; Pickle, Wu, & 
Burbank-Schmitt, 2014).  Despite pervasive endorsements as first-line contraception from 
leading healthcare institutions, LARC use in the US remains low  (ACOG, 2011; ACOG, 2012; 
CDC, 2010; Ott & Sucato, 2014).  Data from 2012, the most recent available, measuring the
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 most effective method of contraception used in the last month by women at risk for unintended 
pregnancy—those who are sexually active, not currently pregnant, postpartum, or otherwise 
infertile—lists LARC use at 11.6% compared to 25.9% for the pill and 15.3% for male condoms, 
while 10% used no method at all (Guttmacher Institute, 2016).  
Unintended Pregnancy in North Carolina 
The unintended pregnancy rate in North Carolina (NC) in 2010, the most recent data 
available, was 54% (Kost, 2015).  In the same year, 74.8% of these unplanned births were 
publically funded through programs such as Medicaid, Children’s Health Insurance Program, or 
Indian Health Services, again exceeding the national average of 68% (Kost, 2015).  Furthermore, 
of the $858.3 million in expenditures, paid for by both the federal and state government, for 
unintended pregnancies, the state was responsible for covering $214.7 million (Sonfield & Kost, 
2015).  It is estimated the prevention or reduction of unintended pregnancies in North Carolina 
could save the state upward of $448 million dollars  (Sonfield & Kost, 2015).   
Potential Issues 
 Provider Behavior. While the specifics of provider behaviors as to contraceptive clinical 
practice in North Carolina have not yet been elucidated, and are in fact the particular concern of 
this project, there is ample data from various other state and national sources indicating providers 
may in many instances act as a barrier to LARC access.  The literature postulates provider 
behaviors and their individual contraceptive clinical practice may create difficulty accessing 
LARC methods for their patients, specifically when healthcare providers lack the knowledge and 
training required to insert or council patients on choosing LARC methods (Dehlendorf, Levy, 
Ruskin, & Steinauer, 2010; Harper et al., 2012; Harper et al., 2008).  Further presentation of 
evidence is put forth in the discussion of the available literature.  
  3 
Rural vs. Urban Access. Of particular concern, studies have shown differences in LARC 
availability by rural and urban delineations in states such as Illinois and Wisconsin, where a 
survey of 862 rural primary care physicians found that many did not have training in IUD (87%) 
and implant (41%) placement (Lunde et al., 2014).  In Texas, a survey of family planning 
providers at Title X clinics revealed that urban providers self-reported they were well trained in 
LARC insertion at higher rates than their rural counterparts (75% versus 57%) (Vaaler, 
Kalanges, Fonseca, & Castrucci, 2012).  Rates of LARC use were also higher for patients seen at 
the urban clinics versus the rural clinics for IUDS, 7% vs. 5%, and implants, 1% vs. <1% (Vaaler 
et al., 2012).  This led the authors to conclude that there is a disparity in access to LARC 
methods between rural and urban clinics and that these findings demonstrate both importance of 
LARC training for providers and also the potential impact provider’s knowledge and attitudes 
about LARCs may have on patients choosing LARC methods (Lunde et al., 2014; Vaaler et al., 
2012).  Data such as this is relevant to the discussion of LARC access in NC since the 2010 
census, the most recent data available, NC was classified as having the second largest rural 
population in the nation and in the 2014 census estimate, 80 of is 99 counties are classified as 
rural by having a population density of less than 250 people per square mile or less (Gray, 2015; 
U.S. Census Bureau, 2012).   
The Role of the Nurse Practitioner 
In NC, it has been estimated that 58% of NPs work in primary care settings (Spetz, 
Fraher, Li, & Bates, 2015).  Furthermore, NPs, particularly those working in publicly funded 
clinics, which are known to serve populations at highest risk for unintended pregnancy, have 
been identified as essential providers of contraceptive services (Landry, Wei, & Frost, 2008).   
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Nurse practitioners have been identified as providing quality, primary care services equal 
to and in some measures exceeding that of physicians as measured by physiologic outcome 
measures, patient satisfaction, and cost (Swan, Ferguson, Chang, Larson, & Smaldone, 2015).  
Under the Quality and Safety Education for Nurses Initiative (QSEN) and the Core 
Competencies for Nurse Practitioners developed by the National Organization of Nurse 
Practitioner Faculties, both of which strongly emphasize the importance of possessing analytic 
skills for evaluating and providing evidence-based care, there is an expectation to perpetually 
improve one’s practice (Cronenwett et al., 2007; Thomas et al., 2012).  To meet this competency 
expectation, NPs must consistently work to grow their knowledge base and practice through the 
addition of new skills and adoption of new protocols and guidelines. 
Providers & Contraceptive Counseling.  The CDC recommends to counsel all patients about 
the full range and effectiveness of contraceptive options for which they are medically eligible” 
by their providers (CDC, 2013).  In conjunction with the U.S. Office of Population Affairs in 
2014, and updated in 2016, they released report called “Providing Quality Family Planning 
Services” (Gavin et al., 2014; Gavin & Pazol, 2016).  This guidance is for all providers who 
provide contraceptive services- from primary care providers to OB/GYNs.  In the report, is the 
recommendation that providers use a tiered approach when discussing contraceptive methods by 
starting with the most effective and first-line recommended methods first and working their way 
down to the least effective method (Gavin et al., 2014).  In this way, the comprehensive 
contraception counseling aims to give women the information they need to choose the most 
appropriate contraception method for them based on a variety of factors including health history, 
lifestyle, and personal attitudes regarding potential side effects among others (Dehlendorf, 
Krajewski, & Borrero, 2014).  A unique clinical situation is created by the intersection and 
  5 
interaction of medical science with patient preference and personal beliefs due to the very 
personal nature of choosing contraception.  This is not seen to the same degree, when providers 
counsel patients on medication options for blood pressure management where JNC-8 guidelines 
leave far less leeway in the treatment modality recommendations than the CDC MEC for 
contraception does.  Provider’s limited adherence to evidence-based guidelines regarding LARC 
methods has been implicated as a potential reason for their lower rates of use in the U.S. (Harper 
et al., 2013).  The impact of contraceptive counseling is evident in multiple studies describing 
how selection of a new contraceptive method is largely influenced by provider behaviors, 
specifically mentioning or not mentioning certain methods, or directly recommending others  
(Bitzer et al., 2013; Dehlendorf et al., 2010; Harper, Brown, Foster-Rosales, & Raine, 2010).   
Contraceptive counseling is most effective when provided with evidence based 
recommendations, non-judgment, and clarity through which women may be empowered to 
choose the method which is most effective and easy for her for successful family planning.  
Project Purpose 
 This project aims to identify contraceptive clinical practice trends among nurse 
practitioners in the North Carolina.  Specifically, the objectives of the project are to identify 
clinician practice patterns and attitudes toward contraceptive care in the following ways:  
1. To examine whether contraceptive clinical practice (CCP) pattern varies by graduate 
practice program preparation of the provider.  
2. Explore factors related to routine counseling of LARC methods by providers.  
The answers to these questions will also serve as an early needs assessment in evaluating 
current CCP among providers as to contraceptive counseling, current skill level for LARC 
insertion technique, and provider interest in receiving further training in LARC methods. 
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 CHAPTER 2 
  LITERATURE REVIEW 
Healthy People 2020, a public health initiative focused on reducing health disparities 
among Americans, made family planning one of its strategic objectives (Healthy People 2020, 
2015).  Goals include increasing the overall proportion of pregnancies that are planned and 
reducing the percentage of women who become pregnant despite using reversible forms of 
contraception (Healthy People 2020, 2015).  In response to the widespread health and economic 
effects of unintended pregnancies, Healthy People 2020 (2015) lists improving pregnancy 
planning, spacing, and preventing unintended pregnancies as a goal.  There is no better phrasing 
than that used by Pace et al., …“family planning protects the health of women, children and 
communities, [and] it is a quintessential primary care service” (Pace, Cohen, & Schwarz, 2011).  
LARC’s superior effectiveness, shown in study after study, gives us a chance to use an upstream 
solution—access to the highest efficacy contraception—to address downstream problem, 
unintended pregnancy.  This leads us to an inevitable, and proven conclusion—unintended 
pregnancies would be much less common if rates of LARC use were to increase among 
American women (Harper et al., 2015).  Therefore, it is important to ask the question—what role 
can primary care providers (PCPs) play in a women’s decision to use contraception and the 
receipt of family planning services among their patients? 
To understand role LARC availability in primary care can play in reaching these goals, 
we have to first understand the sheer number of unintended pregnancies that occur while women 
 7 
 are using other methods of birth control and the lasting effects of these unintended pregnancies.  
This literature review will therefore first address the consequences of unintended pregnancies, 
public health and economic, then examine the historical context of LARC use in America which 
led to its decline in popularity and contributed to many of the pervasive misunderstandings 
providers still have about LARC use.  Then we will present findings on LARC training rates 
among providers, provider behaviors that negatively impact LARC availability, and a possible 
solution to low training rates and provider misconceptions about LARC use—increasing 
attendance at post graduate training programs—and how the proposed project will provide data 
to help further this goal. 
Consequences of High Unintended Pregnancy Rates 
Public Health.  Unintended pregnancies are a public health problem, which affect 
approximately 3 million pregnancies in the U.S. each year (Pickle et al., 2014).  Studies show 
that women who have unplanned pregnancies are at increased risk of delaying prenatal care, 
experiencing maternal depression, and suffering physical violence during pregnancy (Joyce, 
Kaestner, & Korenman, 2000; Pickle et al., 2014).  Meanwhile, their infants are more likely to 
have low birth weights and are at higher risk for birth defects (D'Angelo, Gilbert, Rochat, 
Santelli, & Herold, 2004; Kaye, 2012; Pickle et al., 2014).  As these children grow, they are also 
more likely to live in poverty, experience adverse physical and psychological outcomes, and 
have lower educational attainment than their peers  (Ng & Kaye, 2012; Pickle et al., 2014).    
Economic. Simply stated, unintended pregnancies are expensive and taxpayers primarily 
shoulder this economic burden.  Two separate economic studies estimated that unintended 
pregnancies cost taxpayers in excess of 11 billion dollars annually (Monea & Thomas, 2011; 
Sonfield, Kost, Gold, & Finer, 2011).  A third attributes 2.5 billion of that total directly to 
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unintended pregnancies resulting from imperfect adherence to contraceptive methods (Trussell, 
2007).  It is estimated that if a little as 10% of women aged 20-29 switched from oral 
contraceptives to LARC methods the total savings would be $288 million per year (Monea & 
Thomas, 2011; Trussell et al., 2013). 
Contraceptive Trends 
Increasingly, primary care providers are providing contraceptive services to their patients 
in the U.S.—there were 11.5 million visits to primary care providers for contraceptive services in 
2010 (Pickle et al., 2014).  This number is expected to increase with the ACA and the mandate to 
cover contraception, though more recent numbers have not been available.  In selecting 
contraceptive methods, providers and patients commonly select the pill, the patch, the vaginal 
ring, and male condoms.  All of these methods have high typical-use, first year failure rates 
ranging from 18% for male condom to 9% for the pill (CDC, 2014).  Of the unintended 
pregnancies, each year, only 5% of these occur in women using birth control consistently and 
correctly at each and every sexual encounter (Daniels, Daugherty, & Jones, 2014; Guttmacher 
Institute, 2015; Kavanaugh, Jerman, Ethier, & Moskosky, 2013).  High typical-use failure rates 
are concerning because many women remain unaware that they are not using their chosen birth 
control methods in a way that would meet the definition of consistently and correctly.   
Statistically, in any given year, approximately 70% of the nearly 61 million U.S. women of 
childbearing age, 15-44 years, are at risk of experiencing an unintended pregnancy (Guttmacher 
Institute, 2015).  In other words, there are 43 million women in need of adequate contraceptive 
counseling and services each year (Guttmacher Institute, 2016).  Among these women, 18% will 
use contraceptive inconsistently and will make up 41% of unintended pregnancies, 14% will not 
use contraception at all or will have a gap in use that lasts for 1 months or longer and these 
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women will account for 54% of the unintended pregnancies that year (Guttmacher Institute, 
2016).  It is precisely the issue of inconsistent or intermittent use that puts women at risk and 
short acting reversible contraceptive methods such as the pill, patch, and vaginal ring allow for 
intermittent and inconsistent use by their very design and nature.    
Long Acting Reversible Contraception Methods 
When discussing LARC methods, it is important to clarify that the title describes two 
forms of intrauterine devices, non-hormonal and hormonal, and one type of hormonal implant. 
Collectively, LARC methods are known to provide highly effective, non-user dependent 
contraception (CDC, 2014).  These methods include the non-hormonal Copper T 380A (Cu-
IUD), the hormonal levonorgestril intrauterine systems (LNG-IUS), and the etonogestrel implant 
(ENG-Implant), Nexplanon.  All of which have exceedingly low first year typical-use failure 
rates (CDC, 2014).  Rates vary by LARC method, but each are considered as effective as 
permanent options, such as sterilization, but are reversible with rapid return to fertility upon 
discontinuation—0.05% for Nexplanon, 0.2% for LNG-IUS, and 0.8% for Cu-IUD (CDC, 2014).  
As such, current guidelines for contraceptives including ones by CDC, ACOG, and AAP 
universally promote LARC as the first-line contraceptive recommendation for almost all women 
excluding those with distorted uterine cavities (LNG-IUS and Cu-IUD), current breast cancer 
(LNG-IUS, Nexplanon), Cervical cancer awaiting treatment (LNG-IUS and Cu-IUD), 
endometrial cancer (LNG-IUS and Cu-IUD), gestational trophoblastic disease (LNG-IUS and 
Cu-IUD), and AIDS (LNG-IUS and Cu-IUD) (ACOG, 2012; CDC, 2010; Ott & Sucato, 2014).   
These recommendations are meant to guide contraceptive counseling such that women are 
presented with the most effective methods first and foremost, not dictate that all women must use 
choose to use these methods.  
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Intrauterine Contraception 
 Currently in the U.S there are five intrauterine contraception (IUC) devices available.   
These include the sole non-hormonal method, the Copper T 380A (Paraguard), and four 
levonorgestril secreting intrauterine systems (LNG-IUS): Mirena, Skyla, Liletta, and Kyleena 
(Bayer, 2016a; Bayer, 2016b; Bayer, 2016c; Merck, 2016; Odyssea Pharma, 2016; Teva 
Women's Health, 2014).  Each of these methods may be placed by a trained health care provider 
in an outpatient setting and require minimal additional clinic expenditure for supplies beyond 
those already required for routine pelvic examinations. 
 Copper T 380A.  The Copper T 380A IUD, approved for use for up to 10 years, is a non-
hormonal, 32mm wide and 36mm tall polyethylene T-shaped copper-containing device made 
radio-opaque with the addition of barium sulfate (Teva Women's Health, 2014).  The device has 
approximately 176mg of copper wire coiled along the vertical stem and an additional 68.7mg 
collar on each of the horizontal arms providing a total copper surface area of 380 ± 23mm2 (Teva 
Women's Health, 2014).  The mechanism of contraception action is disruption of sperm 
transport, fertilization, and prevention of implantation through the continuous release of copper 
ions into the uterine cavity (Teva Women's Health, 2014).  The Copper T 380A is the one LARC 
method that may also be used as emergency contraception within five days of unprotected sexual 
intercourse (Teva Women's Health, 2014).   
 LNG-IUSs.  Currently there are four types of LNG-IUSs on the market: Mirena, Skyla, 
Liletta, and the most recent, Kyleena, approved in October 2016 (Bayer, 2016a; Bayer, 2016b; 
Bayer, 2016c; Odyssea Pharma, 2016).  The mechanism of contraception action of each is 
similar whereby the IUS releases a slowly diminishing rate of levonorgestril over the approved 
period of use and this prevents pregnancy through a several mechanisms: thickening the cervical 
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mucus to prevent passage of sperm into the uterus, inhibition of sperm capacitation or survival, 
and alteration of the endometrium to prevent implantation.  The variation in each of the LNG-
IUSs available comes from the and FDA approved duration of use, size of the device, the initial 
volume of LNG contained in the device, and the in vivo amount of levonorgestril released over 
time. Each of these methods may be removed at any point after insertion but must be removed by 
the end of their approved duration of use time frame.  The LNG-IUSs also provide non-
contraceptive benefits for some women by reducing painful or heavy menstrual cycles and many 
women report either stark reduction in menstrual flow or complete cessation of menstrual cycles 
while the device is in place (Rodriguez & Darney, 2010).  Therefore, unlike the Copper T 380A, 
the LNG-IUS devices offer secondary benefits beyond contraception.  
 Mirena.  Mirena was the first, of the LNG-IUSs approved for use in the U.S. Like many 
of the others, Bayer HealthCare Pharmaceuticals Inc. manufactures it, and it’s basic T-shaped 
design with the vertical stem acting as a drug reservoir served as the prototype for the various 
LNG-IUSs that followed (Bayer, 2016b).  The polyethylene frame measures 32 mm wide and 32 
mm long and the drug reservoir holds 52 mg LNG(Bayer, 2016b).  The initial LNG release rate 
is 20 mcg/day up to day 90 and then falls to 18 mcg/day after 1 year and finally reaches 10 
mcg/day after 5 years.  A stable serum concentration between 150 – 200 pg/mL of LNG is 
maintained throughout the 5-year duration of use (Bayer, 2016b).  
 Skyla.  Skyla has been approved for use for up to 3 years for pregnancy prevention. The 
frame measures 28mm wide by 30mm long and the drug reservoir contains 13.5mg of LNG 
(Bayer, 2016c).  The approximate release rate is 14 mcg at 24 days, 10mcg/day after 60 days, 
and 5 mcg/day at 3 years. Bayer (2016c)estimates the average LNG in vivo release rate to be 
approximately 6 mcg/day over 3 years(Bayer, 2016c).  
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Liletta.  Liletta has been approved for pregnancy prevention for up to 3 years (Odyssea 
Pharma, 2016).  The frame measures 32 mm wide and 32 mm long and similar to the Mirena, the 
drug reservoir contains 52mg of LNG (Odyssea Pharma, 2016).  The release rate of LNG starts 
at 18.5mcg/day and progressively declines to approximately 16.3 mcg/day at 1 year, 14.3 
mcg/day at 2 years, and 12.6 mcg/day at 3 years (Odyssea Pharma, 2016).  
Kyleena.  Kyleena is the newest LNG-IUS to reach the market and has been approved for 
pregnancy prevention for up to 5 years (Bayer, 2016a).  The frame measures 28 mm wide and 30 
mm long and the drug reservoir contains 19.5 mg of LNG (Bayer, 2016a).  The release rate of 
LNG starts at 17.5mcg/day after 24 days, and progressively declines to approximately 15.3 
mcg/day after 60 days, to 9.8 mcg/day at 1 year, then 7.9 mcg/day at 3 years, and 7.4 mcg/day at 
5 years (Bayer, 2016a).  Bayer (2016a) estimates the average LNG in vivo rerelease rate to be 9 
mcg/day over 5 years.   
Etonogestrel Contraceptive Implant  
 The only etonogestrel contraceptive implant (ENG-Implant) on the market is Nexplanon, 
it is manufactured by Merck and is an improvement on the single rod system, Implanon, through 
the addition of a radiopaque material which allows the implant to be viewed on x-ray (Merck, 
2016).  The ENG-Implant is a sub dermal rod-shaped implant impregnated with 68mg 
etonogestrel and approved for 3 years of use (Merck, 2016).  The mechanism of contraceptive 
action is similar to that of the LNG-IUS whereby absorption of the hormone causes suppression 
of ovulation, thickening of cervical mucous to prevent sperm from entering the uterus, and 
thinning of the endometrial lining to prevent implantation (Merck, 2016).  Mean serum 
concentrations of etonogestrel were 1200 (± 604) pg/mL at two weeks after insertion and 
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decreased gradually to 202 (±55) pg/mL at 1 year, 164 (±58) pg/mL at 2 years, and 138 (±43) 
pg/mL at 3 years (Merck, 2016).  
Historical Perspective of LARC Use in the US 
 The Dalkon Shield’s Lasting Legacy.  Encouraging providers to integrate LARC 
methods in their practice is made difficult by the troubled history many providers and patients 
associate with LARC.  In the 1970’s the Dalkon shield IUD made national news when use was 
associated with cases of both pelvic inflammatory disease (PID) leading to infertility and death 
by septic shock (Hubacher, 2002; Strasser, Borkowski, Couillard, Allina, & Wood, 2016).  The 
Dalkon shield was later removed from the market and the defect that led to these complications, 
a multifilament string, is not used in modern LARC methods (Cheng, 2000; Strasser et al., 2016).  
The sustained fallout from this tragedy is visible today in the ubiquity of misconceptions among 
providers—the most common being that many LARC methods are inappropriate for nulliparous 
women or those who plan to have more children (Hubacher, 2002; Lewis, Darney, & Thiel de 
Bocanegra, 2013; Russo, Miller, & Gold, 2013).  Despite extensive evidence documenting the 
safety of modern LARC methods, many providers are hesitant to recommend LARC or perform 
insertions for adolescents or nulliparous women (Greenberg, Makino, & Coles, 2013; Tanfer, 
Wierzbicki, & Payn, 2000).  Additional reasons, cited in the literature, providers decline to offer 
LARC services, include inadequate reimbursement, lack of training, perceived low patient 
interest on the part of the provider, and provider concerns about procedure risk and litigation 
(Harper et al., 2008; Strasser et al., 2016).    
Proven Safety.  Substantial evidence intending to counter balance these fears, put 
providers and patients at ease, and validate the safety and efficacy of modern LARC devices 
exists.  Over the past decade, many well-respected authorities have endorsed LARC methods 
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starting with the World Health Organization’s (WHO) Department of Reproductive Health and 
Research.  The WHO released their practice recommendations in 2004 outlining LARC methods 
as safe and highly effective contraception options suitable for all women (WHO, 2004).  Three 
years later, in 2007, the ACOG endorsed LARC use in nulliparous women including adolescents 
(ACOG, 2007).  Shortly after, in 2010, the CDC released revised medical eligibility criteria for 
providers advising that LARC methods have very few contraindications for use in women of all 
ages, as described earlier (CDC, 2010).  In 2012, the ACOG released a grounding breaking 
committee opinion endorsing LARC methods as first-line contraception for all women, meeting 
the CDC medical eligibility criteria, including adolescents (ACOG, 2012) (Appendix A).  
Finally, in 2014, the AAP released a committee opinion encouraging pediatricians to educate 
patients about LARC methods and either acquire the skills to perform insertions themselves or be 
knowledgeable of providers available for referral  (Ott & Sucato, 2014).   
“Women don’t want LARC”.  As discussed earlier, LARC use in the U.S. is 
exceedingly low as compared to European and Asian counterparts, where rates are 17.1% and 
27% respectively (Buhling, Zite, Lotke, & Black, 2014).  Anecdotally this is explained by 
American women’s discomfort with these methods (L. A. Joel, personal communication, 
November 20, 2015).  However, multiple studies have shown that American women embrace 
LARC use under certain, easily reproducible, conditions.  The CHOICE Project, a prospective 
cohort study of 10,000 women aged 14-45 desiring to avoid pregnancy for greater than a year, 
provided standardized contraception counseling and free contraception to participants (Secura, 
Allsworth, Madden, Mullersman, & Peipert, 2010).  They found when LARC was discussed as 
first-line contraception with every woman, every time and cost was eliminated, 67% of 
participants chose LARC methods (95% CI, 65.3-69.0) (Secura et al., 2010).  A study comparing 
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rates of LARC use between a convenience sample of 488 female family planning providers aged 
25-44, including physicians and advance practice clinicians, and female respondents of the same 
age from the 2011-2013 National Survey of Family Growth (NSFG) showed LARC use varied 
widely between the NSFG respondents and the providers, 12.1% and 41.7% respectively (Stern 
et al., 2015).  While beyond the scope of the study to definitively explain this difference, the 
authors attributed the variance to knowledge of LARC methods and access (Stern et al., 2015).    
Modern Barriers to Access 
As discussed previously, PCPs saw 11.5 million visits in 2010 for family planning and 
contraception acquisition (Pickle et al., 2014).  This number is only expected to increase with the 
implementation of the Affordable Care Act, which includes a provision requiring full coverage 
for contraception counseling and services at no cost to the patient (Pickle et al., 2014; U.S. 
Department of Health and Human Services, 2014).  However, changes to this provision may be 
coming given the political flux around insurance coverage requirements and healthcare laws in 
the country.  Regardless of the political direction, ideally, primary care providers are prepared to 
offer these women the same options for family planning they would receive from an obstetrician-
gynecologist (OB-GYN) or women’s health NP (WHNP) but too often, this is not the case 
(Cheng, 2000; Harper et al., 2013; Vaaler et al., 2012).  If the same holds true among NC NPs 
providing contraception services in primary care clinics, then these practitioners are a prime 
target for future practice improvement interventions such as LARC training programs to improve 
access.  
Providers Lack Training.  The small percentage of providers trained in LARC methods 
is cited countless times in the literature as a barrier to LARC access (Greenberg et al., 2013; 
Harper et al., 2013; Nobiling & Drolet, 2012; Potter, Koyama, & Coles, 2015).  Three major 
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studies have released data specific to the disparities on LARC education and provision between 
primary care providers and specialists.  The first, a study of 816 physicians, NPs, and PAs 
working in the California Family Planning Program (CFPP) for low-income women found that 
among participants only 4% of OB-GYNs were untrained in LARC methods while rates for other 
physician specialties, and the advance practice clinicians, were substantially higher at 32% and 
41% respectively (Harper et al., 2008).  In the second study, a survey exclusively examining 
LARC training among 586 NPs, who routinely provide contraceptive care, 66% of WHNPs 
reported IUD training compared to 12% of primary care NPs (Harper et al., 2013).  The trend 
continued for contraceptive implants with 42% of WHNPs trained in Nexplanon compared to 
10% of family practice NPs (Harper et al., 2013).  The final study of 249 physicians and 
advanced practice clinicians working in California’s Family Planning, Access, Care, and 
Treatment (Family PACT) program, examined the impact of a provider training session on 
participant knowledge and provision of LARCs found that 61% of participants received no 
training in LARC methods during their residency/core training (Lewis et al., 2013).  These 
numbers make it very clear that there is room for improvement among primary care providers 
who provide contraception services, the exact population this project aims to survey.  
Furthermore, as discussed earlier, there are proven differences between urban and rural 
providers, in multiple states, as to training, comfort, and knowledge of LARC methods (Lunde et 
al., 2014; Vaaler et al., 2012). 
Misconceptions Influencing Clinical Practice 
 Further research has identified pervasive misconceptions many providers have regarding 
LARC methods, which have an effect the contraceptive counseling providers give patients and 
therefore ultimately affect LARC access.  In semi-structured interviews with 42 women, 
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participants indicated while the final decision making power over contraception choice was 
theirs, comprehensive counseling on all methods and a shared decision making process with their 
providers weighed heavily on their final choice (Dehlendorf, Levy, Kelley, Grumbach, & 
Steinauer, 2013).  When providers harbor these misconceptions, it affects the quality 
contraception counseling provided to patients and creates missed opportunities for LARC 
discussion with patients (Dehlendorf et al., 2013).  Furthermore, the CHOICE project discussed 
earlier demonstrates the power of standardized contraception counseling highlighting LARC 
methods as first line on patient’s choices of contraception (Secura et al., 2010).   
Patient Selection.  Pervasive misconceptions surround criteria for appropriate patient 
selection; this is particularly concerning in light of the WHO, CDC, ACOG, and AAP 
recommendations (ACOG, 2007; ACOG, 2009; CDC, 2010; Ott & Sucato, 2014; WHO, 2004).  
A study of 635 office based providers and 1,324 Title X clinic providers (physicians, PAs, 
certified nurse midwifes, NPs, and nurses) showed 30% of percent of respondents had 
misconceptions about the safety of IUDs in nulliparous women (Tyler et al., 2012).  The CFPP 
survey showed providers had erroneous knowledge in appropriate patient selection based on 
comorbidities, 24% reported IUDs are inappropriate in women with diabetes, 66% reported they 
would not insert a levonorgestril-releasing IUD in a smoker, though neither of these are 
contraindications for use in either population (Harper et al., 2008).  Another survey of 137 
providers, physician and advance practice clinicians, in Saint Louis showed 29% incorrectly 
believed IUD methods increased the risk of PID (Madden, Allsworth, Hladky, Secura, & Peipert, 
2010).  Increased provider knowledge of and positive attitudes toward LARC is correlated with 
increased comfort in recommending these methods  (Postlethwaite, Shaber, Mancuso, Flores, & 
Armstrong, 2007).    
  18 
Progress Through Training Programs  
A proven way to address provider misconceptions, increase provider knowledge and 
comfort with LARC methods, and teach insertion techniques is through attendance at training 
sessions.  Multiple independent studies have proven the effectiveness of training programs in 
addressing the three key ways providers act as barriers to access: 1) lack trained providers, 2) use 
of overly stringent patient selection criteria, 3) failure discuss LARC options with patients  
(Branum & Jones, 2015; Lewis et al., 2013; Postlethwaite et al., 2007; Rubin, 2013).  The 
Family PACT study, described earlier, found statistical significance after training in provider 
understanding of appropriate candidate selection (p<0.001), provision of IUDs in the 6 months 
after training compared to the 6 months prior (p<0.01), and participating sites saw an increase in 
IUD use compared to their nonparticipating comparison sites (p<0.01) (Lewis et al., 2013).  A 
recent randomized trial of 40 reproductive health clinics across the U.S., which served 1,500 
women during the study, showed that the intervention, an evidence-based training program in 
LARC insertion and contraception counseling was effective in changing clinical practice and 
impacting LARC provision as compared to the standard of care sites which received no training 
(Harper et al., 2015).  The intervention proved to be successful in initiating practice change; 
women seen at the interventional sites reported receiving counseling on LARC methods at higher 
rates, 71% vs. 39% (odds ratio 3.8, 95% CI 2.8-5.2), and more opted for LARC methods, 28% 
vs. 17% (odds ratio 1.9; 95% CI 1.3-2.8) (Harper et al., 2015).  The pregnancy rate 12 months 
out was lower at interventional clinics than standard of care clinics and the authors attribute this 
to the increase in LARC counseling and provision at the interventional clinics (Harper et al., 
2015).   
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 As training programs, such as the “Beyond the Pill” program developed by Harper et al. 
(2015), are shown to be effective in the literature, the widespread diffusion and sweeping 
implementation of these programs is key to initiating practice change for providers.  However, 
these programs have only been studied in the context of participants recruited as part of larger 
research projects.  In order to market these programs and recruit participants outside of research 
studies, an initial step is first determining the current CCP and educational needs of providers in 
the area.   
Conceptual and Theoretical Framework 
Introduction to Diffusion of Innovation  
 The Diffusion of Innovation Theory (DOI), is a social science theory, which aims to 
explain how, over time, an idea, product, or technology gains momentum and spreads through a 
specific population finally resulting either in widespread adoption or failure (Rogers, 2003).  The 
theory postulates three basic clusters of influence affect the rate and spread of change (Berwick, 
2003; Rogers, 2003).  These are, perceptions of the innovation, characteristics of the people who 
adopt or fail to adopt the innovation, and contextual factors such as location, leadership, and 
management (Berwick, 2003; Rogers, 2003).  Interventional strategies for the theory include the 
creation of a change agent, who works to spread information and knowledge to others within 
their sphere of influence and supplying resources to help addressing contextual factors impeding 
adoption (Berwick, 2003; Dearing, 2009; Rogers, 2003).  In healthcare, DOI has been used to 
explain the adoption or failure of clinical behavior change including the introduction of new 
treatment techniques, new medications, and new guidelines.  It is being used here to understand 
trends in CCP and the level to which practice change has been incorporated in light of the recent 
changes to contraception guidelines discussed earlier.  
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Application.  Among providers, the adoption of LARC methods, through participation in 
post-graduate training, in family practice has been slow as shown by the shortage of providers in 
primary care trained in insertion techniques (Harper et al., 2015; Lewis et al., 2013).  The 
majority of PCPs do not receive training in LARC method insertion during their graduate 
programs and therefore must seek out learning opportunities once they have started practicing 
(Lewis et al., 2013).  This theory offers an explanation of the observed trajectory of adoption, 
and also discusses concepts that need to be addressed in interventions that aim to change that 
trajectory (Dearing, 2009; Fink, Thompson, & Bonnes, 2005; Moulding, Silagy, & Weller, 
1999).   
LARC & The DOI.  It is important to acknowledge LARC methods as the innovation in 
question.  If the innovation itself is unacceptable to providers, diffusion will fail.  There are five 
elements of an innovation that determine if adoption will occur: relative advantage, 
compatibility, complexity, trialability, and observability (Rogers, 2003; Sanson-Fisher, 2004).    
Relative advantage.  Relative advantage is the degree to which an innovation is perceived 
as better than the idea it supersedes (Rogers, 2003; Sanson-Fisher, 2004). There is ample proof 
the literature that LARC methods are more effective than their short acting reversible 
counterparts (CDC, 2014; Harper et al., 2013).  
Compatibility.  Compatibility describes the extent to which potential adopters’ 
perceptions of the innovation match their existing values, experiences, and needs (Rogers, 2003; 
Sanson-Fisher, 2004).  In the literature, providers often express the desire for additional training 
in LARC methods, indicating an underlying acceptance of the innovation as compatible with 
their needs (Harper et al., 2015).    
  21 
Complexity.  Complexity measures perceptions of difficulty associated with the 
innovation (Rogers, 2003; Sanson-Fisher, 2004).  While providers express a desire for training, 
incorporating this into clinical practice proves more complex, as it requires behavior change in 
all staffing levels.  The proven success of many clinics in incorporating LARC methods in 
practice indicates this is a surmountable obstacle  (Harper et al., 2015; Jeffreys & Clark, 2012; 
Secura et al., 2010).   
Trialability.  Trialability describes the degree to which an intervention can be trialed and 
modified in practice (Rogers, 2003; Sanson-Fisher, 2004).  There is very little individual 
trialability to LARC methods, since training is binary; providers have either received training or 
they have not.  However, providers are not mandated to insert LARC methods themselves just 
because they possess the skills to do so since there is also the concept of competency to consider, 
as providers who receive training are not immediately competent in insertion techniques.  This is 
particularly true of the IUDs, as insertion requires a far more nuanced technique and skill than 
that of the LNG-Implant.  Therefore, trialability exists in the sense that after training, providers 
may offer and insert LARC methods for a period of time before deciding that it is not feasible in 
their individual practice model.  There also exists trialability in the way that providers who are 
not trained in insertion techniques may simply change their CCP to reflect inclusion of LARCs 
and later referring patients to providers who do perform insertions.   
Observability.  Observability describes the degree to which results of the innovation are 
visible (Rogers, 2003; Sanson-Fisher, 2004).  The potential to reduce rates of unintended 
pregnancy with LARC methods were initially theoretical, but recent publications have shown 
demonstrable rate reductions (Harper et al., 2015; Speidel, Harper, & Shields, 2008).   
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When looking at the balance of these five elements, it is clear that as an innovation, 
LARC methods pass the litmus test of acceptability for providers.  This is further supported by 
the slow but continuous rise in use among American women, indicating that they too find it 
acceptable as an innovation  (Branum & Jones, 2015).    
The diffusion of innovation theory states that for early efforts to gain traction, they must 
have significant investment of resources or heavily dedicated early adopters (Rogers, 2003; 
Sanson-Fisher, 2004).  It is unknown if diffusion of LARC methods among clinicians in North 
Carolina had either of these or a combination of the two to drive diffusion forward.  However, 7 
years have passed since the CDC first changed their MEC to reflect the safety of LARC use in 
women of all ages, and 5 years have passed since the ACOG endorsed use of LARC methods as 
first line contraception for all women, and this project will help to determine how readily these 
recommendations have been embraced by practitioners and if practice change has diffused out 
among primary care providers in the state such that their contraceptive clinical practice might 
match that of their peers in women’s health.  However, this is not reflected in the available 
literature and therefore it is hypothesized that rapid diffusion has not yet occurred.  It is expected 
that the CCP pattern of providers will vary according to their graduate practice program and 
providers who trained in graduate programs specific to women’s health (WHNP/OGNP or CNM) 
will demonstrate a CCP pattern that most closely adheres to current guideline recommendations 
for LARC use.     
 23 
 CHAPTER 3 
  METHODOLOGY 
A modified the National Pregnancy and HIV/STI Prevention Survey (Harper et al., 2013) 
was distributed to the advanced practice nurses on the list-serve of North Carolina Board of 
Nursing between November 14th, 2016 and January 9th, 2017.  The University of North Carolina, 
Chapel Hill Institutional Review Board and Office Human Research Ethics approved the study. 
The results were analyzed in collaboration with (Yeun, Marron) and assistance from the Howard 
W. Odum Institute for Research in Social Science (ODUM). 
Subjects 
Participants were advanced practice registered nurses, identified through a data request 
made to The North Carolina Board of Nursing (NCBON) for the list of all licensed advance 
practice registered nurses in the state (NCBON, 2016).  The list is publically available for a 
nominal fee and released by the NCBON for the specific purpose listed in the application.  Data 
provided includes practitioner name, address, county, email address (where available), primary 
specialty, secondary specialty, and practice setting (NCBON, 2016).  The database is updated in 
real time and contains all NPs in the state who are active and in good standing at the time of the 
request (personal communication, L. Fogel, February 11, 2016).  Data provided was up-to-date 
as of October 10th, 2016.    
 Of the 6,622 NP names provided as part of the original data set, 41 did not have 
associated email addresses and of the 308 CNM names provided, 7 did not have associated email 
addresses.  Therefore, the original mailing was sent to a total recipient list of 6,859 unique email 
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 Process 
First, an email introducing the study with a link to the survey was sent to the list-serve.  
Participation was incentivized with entry to a drawing for a gift card, with varying amounts, 
upon survey completion with multiple winners (4) drawn from the participant pool.  At weeks 3, 
5, and 7 a reminder email was sent to the same list-serve which had been modified to remove 
emails of those who had already participated, as reflected by entering the drawing, or had opted 
out of participation through the opt-out link provided.  The survey remained open for a total of 8 
weeks with total data collection taking place between November 14th, 2016 and January 9th, 
2017.    
Data Collection.  Survey data was collected and stored using Qualtrics Research Suite, 
an online survey tool available to students at The University of North Carolina- Chapel Hill.  
Qualtrics allows for anonymous survey participation, easy data downloads to multiple formats 
for analysis, and has been approved by the UNC IRB for research activities.  
Study Survey.  A 40-item questionnaire tool was adapted from the “National Pregnancy 
and HIV/STI Prevention Survey” with permission from Dr. Cynthia Harper at The University of 
Southern California-San Francisco (Harper et al., 2013) (Appendix B).  The original 65 survey 
questions were developed through 31 formative, qualitative interviews with clinicians including 
physicians, nurse practitioners, and physician assistants (Harper et al., 2013; Henderson, Sawaya, 
Blum, Stratton, & Harper, 2010).  Question adaptation was performed with guidance from 
ODUM faculty.  Questions were modified to update current market availability of LARC 
methods, clarify questions to reflect differences between IUDs and Implants, and clarify the 
types of visits in which provision of contraceptive counseling practice was being asked.  
Additional demographic questions were added to allow further investigation into differences 
  25 
between rural and urban areas of the state.  The original survey underwent reliability—
Cronbach’s alpha, with reliability coefficients of between 0.77 and 0.88, was used during scale 
creation—and validity tests as part of its initial development (Harper et al., 2008).  The final 
survey has skip logic applied with the shortest logic path ending after a single question and the 
longest after 40 questions.  Of the 40 questions, 10 are demographic questions inquiring about 
the provider’s age, educational background, practice setting, and patient population.  Twenty-
eight questions focus on CCP and LARCs.  These questions evaluate provider prescriptive 
behavior, perception of patient interest in LARCs, contraception methods currently discussed 
when counseling patients, and provider decision making in discussing and recommending LARC 
methods to patients.  One question assesses the participant’s current interest in receiving LARC 
training and one question allows participants to offer additional comments they may have 
relevant to the survey. 
Approach to Analysis 
 To test the hypothesis that the CCP pattern of providers would vary according to their 
graduate practice program preparation, the primary predictor variable was educational 
background and professional training received by participants (Family Nurse Practitioner, 
Women’s Health Nurse Practitioner/Obstetrics & Gynecology Nurse Practitioner, 
Adult/Geriatric Nurse Practitioner, Pediatric Nurse Practitioner, or Certified Nurse Midwife).  
Average visit times allocated to contraceptive counseling were calculated from free text answers. 
Measurement of clinician knowledge was evaluated against the indications for LARC use as 
determined by the CDC’s Medical Eligibility Criteria for Contraceptive Use (CDC, 2010) 
(Appendix A).  Adherence to the CDC’s MEC in answering these questions indicated a higher 
level of understanding of and practicing to current evidence-based guidelines.   
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Statistical Analysis.  Statistical analysis was performed with assistance from Chuchu 
Yuan and Steve Marron, PhD in the Department of Statistics and Operations Research at The 
University of North Carolina- Chapel Hill. Statistics performed included bivariate analysis using 
ordinal and logistic regressions.  Heather Ba at the Odom Institute at The University of North 
Carolina- Chapel Hill provided additional assistance. 
Data was initially downloaded from Qualtrics in a .CSV file, converted to excel, and then 
uploaded to Stata for early data analysis including frequencies and odds ratios for one question.  
Early data analysis was performed with assistance from Heather Ba at ODUM.  Data was then 
brought to Chuchu Yuan and Dr. Steve Marron for counseling to develop a final analysis plan for 
the two hypotheses.  During a meeting including Dr. SeonAe Yeo, Chuchu Yuan, Dr. Steve 
Marron, and myself a detailed plan was outlined as to how the statistical analysis would be run 
and the survey question data needed.  The raw data was then cleaned to create a new file 
including only the questions required for analysis and only those responses from eligible 
participants.  Statistical analysis was then performed by Chuchu Yuan and returned, via email, 
with odds ratios and p values for each point outlined at the initial meeting.  
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 CHAPTER 4 
     RESULTS 
A total of 1,315 APRNs replied to the survey.  Of those, 996 were judged initially 
eligible by an affirmative answer to the question of whether they had one or more occasions to 
provide contraceptive counseling to their patients in the past 12 months at their current position 
and by answering their graduate practice program preparation.  
Demographics 
 Provider Demographics.  A total of 810 responses served for the analyses.  Final data 
was prepared from responses provided by 472 FNPs, 69 WHNP/OGNPs, 68 AGNPs, 49 PNPs, 
and 115 CNMs.  There were 37 respondents who held dual degrees (10 FNP, WHNP; 8 FNP, 
AGNP; 2 FNP, PNP; 7 FNP, CNM; 2 WHNP, AGNP; 7 WHNP, CNM; 1 AGNP, PNP).   
Overwhelmingly, across all provider types, the respondents were female (Table 1).  
Those trained in women’s health, WHNP/OGNP and CNM, accounted for 25.6% of respondents.  
Providers surveyed worked across all areas of the state with similar representation of urban 
(38.3%), regional/suburban cities (29.4%), and rural (29.7%) areas (Table 1).  Of the 100 
counties in North Carolina only 12 were not represented by at least one respondent in this study. 
These 12 counties are all considered rural areas and include: Allegany, Anson, Camden, 
Cherokee, Chowan, Clay, McDowell, Pamlico, Perquimans, Polk, Transylvania, and Washington 
Counties.  
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 Provider Practice Background.  On average practitioners with graduate preparation specific 
to women’s health (WHNP/OGNP and CNM) saw nearly three times as many patients requiring 
contraception counseling per week, 27.3 ± 14.8 (mean [M] ± standard deviation [SD]), and 19 ± 
21 respectively, compared to the FNPs who saw 9.5 ± 14.4 and the AGNPs who saw 4.7 ± 8.9, 
and more than ten times as many as the PNPs surveyed at 2.8 ± 3.6 (Figure 1).  Overall, 
providers reported having similar quantities of time available to provide contraceptive 
counseling during a patient visit, on average, with FNPs reporting 9 ± 6 minutes (mean [M] ± 
standard deviation [SD]), WHNPs reporting 10 ± 5 minutes, AGNPs reporting 8 ± 8 minutes, 
PNPs reporting 8 ± 6 minutes, and CNMs reporting 10 ± 5 minutes (Figure 2).  
In general, AGNPs excluded as they reported satisfaction at less then 50%, providers 
reported that they felt they had enough time to counsel their patients on the contraceptive options 
available to them, but those in primary care did so at lower frequencies than their women’s 
health peers (Figure 2).  Specifically, among women’s health providers, WHNPs and CNMs, 
satisfaction rates were as high as 82.6% and 73.0%, respectively (Figure 2).  Conversely, 
primary care providers reported lower rates as follows: FNP 68%, AGNP 50.7%, and PNP 
55.1% (Figure 2).  
Participants were asked to indicate if their clinics had anyone else, without prescriptive 
authority (i.e. registered nurses, licensed practical nurses, social workers, or peer counselors), 
available to counsel patients on their contraceptive options.  Primary care providers reported 
working in settings without additional assistance to provide contraceptive counseling to patients 
at double the rate of their peers in women’s health, FNP 55.4%, AGNP 55.1%, and PNP 63.3% 
versus 18.8% WHNP and 37.4% CNM (Figure 3).  Overwhelmingly, all providers felt that 
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LARC methods were safe and that their patients were receptive to learning about LARC 
methods, both IUDs and Implants (Figure 4; Figure 5).  
Variation of CCP Pattern by Graduate Practice Preparation 
It was hypothesized that the CCP pattern of providers would vary according to their 
graduate practice program preparation and providers who trained in graduate programs specific 
to women’s health (WHNP/OGNP or CNM) would demonstrate a CCP pattern that most closely 
adheres to current guideline recommendations for LARC use.  Responses from those providers 
trained in graduate programs specific to women’s health (WHNP/OGNP and CNM) were used as 
the standard to which all other provider’s responses were compared.  
Discussion of vs. In Office Availability of Contraceptive Methods.  Women’s health 
providers discussed all contraceptive methods at consistently high frequencies, as was the 
availability of these same methods (Figure 6).  Conversely, among primary care providers we 
saw far more variation in both the discussion of contraceptive methods as well as the in-office 
availability of many methods (Figure 6).  Of specific interest, LARC methods were discussed by 
women’s health providers at nearly perfect numbers with 100% of WHNPs and 99.1% of CNMs 
reporting discussing the ENG-Implant, 97.1% of WHNPs and 97.4% of CNMs reporting 
disusing the Cu-IUD, and 100% of both WHNPs and CNMs reporting discussing the LNG-IUD 
with their patients (Figure 6).  Frequencies were lower among primary care providers for 
discussion of LARC methods.  For the ENG-Implant, 80.1% of FNPs, 52.1% of AGNPs, and 
89.8% of PNPs reported discussing this method with patients (Figure 6).  Similarly low numbers 
were seen for discussion of IUC methods among primary care providers. The Cu-IUD was 
discussed by 68.9% of FNPs, 46.4% of AGNPs, and 18.4% of PNPs (Figure 6).   
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In-office availability of methods discussed during contraceptive counseling, specifically 
among the LARC methods, were found to be vastly different between women’s health providers 
as compared to primary care providers (Figure 6).  Women’s health providers were again found 
to have LARC methods available to patients at consistently high frequencies.  The ENG-Implant 
was available in-office with 88.4% of WHNPs and 100% of CNMs.  Similarly, high frequencies 
were seen for the IUC methods with 92.7% and 95.6% of WHNPs reporting having the Cu-IUD 
and LNG-IUD available respectively.  Rates for CNMs were similar at 94.7% and 100% for the 
Cu-IUD and LNG-IUD respectively.  Comparatively, rates for in-office availability were much 
lower among primary care providers with only 38.1% of FNPs, 17.4% of AGNPs, and 28.6% of 
PNPs having the ENG-Implant available in-office.  Even lower rates of in-office availability 
were seen for the IUC methods with 30.3% and 35.4% of FNPs reporting availability for the Cu-
IUD and LNG-IUD respectively.  Among AGNPs 7.2% reported having the Cu-IUD available in 
office and 14.9% reported the same for the LNG-IUD.  The lowest rates of in-office availability 
were seen for the CU-IUD and LNG-IUD among PNPs with at only 2% for both methods.  
Routine Discussion of LARC Methods 
Further evaluation of contraceptive method discussion was done to determine if LARC 
methods were being routinely discussed with patients during contraceptive counseling.  
Therefore providers were asked to report the frequency with which they discussed individual 
LARC methods.  Routine discussion was defined as responses indicating providers discussed 
these methods with either “more than half, but not all” or “all” of their female patients to whom 
they had provided contraceptive counseling.  Odds ratios were calculated to determine the 
relative likelihood of LARC discussion during contraception counseling by provider type (Figure 
7).  Results were statistically significant (p=0.00) with women’s health providers four times 
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more likely to routinely discuss the ENG-Implant and 9.5 times more likely to routinely discuss 
the IUC methods with patients during contraceptive counseling than their peers in primary care.  
Consideration of LARC Methods  
Respondents were asked about their decision-making during contraceptive counseling as 
part of a well-woman exam (annual physical) or non-acute follow-up visit when recommending 
an IUD for patients with a variety of lifestyle choices or medical comorbidities.  During analysis, 
combining responses “no” and “don’t know” as one category dichotomized responses.  During 
analysis, provider types were grouped as primary care, FNP, AGNP, and PNP, and women’s 
health, WHNP and CNM (Figure 8).  
Again, vast differences were seen in the responses given by women’s health providers 
and those of the primary care providers.  Significant differences (p= <.0001) were seen in the 
recommendation for an IUD to a nulliparous woman were Women’s health providers 7 times 
more likely to do so than were primary care providers.  Adolescent women seeking an IUD are 9 
times more likely to be recommended one if they see a women’s health provider than if they 
were to have seen a primary care provider, again, a significant result (p= <.0001).  
Of particular interest were the results as to reccomndations for unmarried, cohabitating 
versus unmarried, not cohabitating women.  Essentially, these two populations are the same and 
providers were not given any other information as to their sexual history or number of partners 
when answering the question.  However, unmarried, cohabitating women were 30 times more 
likely to receive a recommendation for an IUD from a women’s health provider than a primary 
care provider and unmarried, not cohabitating women were 10 times more likely to receive the 
same. Data was statistically significant (p= <.0001) for both conditions. 
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Finally, providers were presented with women with more complex gynecologic histories 
including those who had a history of a sexually transmitted infection (STI) within the past two 
years, a history of pelvic inflammatory disease (PID), and a history of an ectopic pregnancy.  
Again, statically significant differences (p= <.0001) were seen in the likelihood of 
recommending an IUD to these women depending on the type of provider answering the 
questions.  Women’s health providers were 7 times more likely to recommend an IUD to a 
woman with a history of STI, 3 times more likely for a woman with a history of PID, and 5 times 
more likely to do so for a woman who had previously experienced an ectopic pregnancy than 
their peers in primary care.    
Provider Concerns Affecting IUD Recommendation 
Providers must weigh a variety of concerns when they consider recommending an IUD 
during contraceptive counseling.  To assess the relative impact of these concerns we asked 
participants to consider a selected set of patient conditions and reflect on their relative level of 
concern for each when considering recommending an IUD.  For data analysis, responses 
indicating a moderate or high level of concern might indicate a provider are unlikely to 
recommend an IUD to a patient with the condition in question.   
Primary care providers reported higher levels of concern for all conditions as compared 
to their peers in Women’s Health (Figure 9).  Adolescence weighed most heavily on the minds of 
primary care providers as women’s health providers were 3.7 times more likely to report low 
level of concern in recommending an IUD to a teenager than primary care providers were, a 
statistically significant result (p= <.0001).  Uterine perforation at insertion was the next most 
concerning condition for primary care providers where women’s health providers were 2.8 times 
more likely to report a low level of concern (p= <.0001).  Consistent with the data seen earlier as 
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to recommendation for patients with a history of STI or PID, we see that these concerns weigh 
less heavily on the minds of women’s health providers than they do for primary care providers 
where women’s health providers are 2 and 1.9 times more likely to report low levels of concern 
for these conditions respectively (p= <.0001).  Finally, women’s health providers were 1.7 and 
2.3 times more likely to report low levels of concern regarding expulsion (p= 0.0113) and 
infertility (p= 0.0010), respectively, than were primary care providers. 
Assessment of MEC Understanding 
A strong understanding of the CDC MEC is essential in order for providers to properly 
counsel their patients on all contraceptive options available to them.  Providers were asked a 
question to assess their understanding of the MEC by asking if they would consider 
recommending a Cu-IUD when certain co-morbidities were present.  During analysis, combining 
responses “no” and “don’t know” as one category dichotomized responses.  Again, provider 
types were grouped as primary care, FNP, AGNP, and PNP, and women’s health, WHNP and 
CNM.  
Data for this section revealed stark differences between women’s health providers and 
primary care providers as to knowledge of appropriate candidate selection for the Cu-IUD as 
outlined in the CDC MEC (Figure 10).  For women with conditions commonly seen in primary 
care including diabetes, obesity, smoking, and hypertension primary care providers were 
consistently, significantly less likely to recommend the Cu-IUD than their peers in women’s 
health (Figure 11).  Women’s health providers were 11 and 12 times more likely to recommend 
an Cu-IUD to women with diabetes and obesity respectively than were primary care providers, a 
significant result (p= <.0001).  Furthermore, additional significant results were seen for women 
identifying as smokers or as having a history of hypertension, women’s health providers were 
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155 and 152 times more likely to recommend a Cu-IUD, respectively, as compared to their peers 
in primary care (p= 0.0004).  
Women’s health providers were only less likely to recommend a Cu-IUD for women with 
three conditions including menorrhagia, dysmenorrhea, and iron deficiency anemia (the only 
statistically insignificant result) (Figure 12).  In these cases, women’s health providers had 0.4 
and 0.7 times lower odds of recommending a Cu-IUD to women with menorrhagia and 
dysmenorrhea respectively, compared to primary care providers (p= <.0001 and p= 0.0494 
respectively).  
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 CHAPTER 5 
    DISCUSSION 
 We saw statistically significant differences among the CCP of primary care providers as 
compared to women’s health providers across a variety of measures all of which both 
individually and collectively have the potential to affect the quality of contraceptive counseling 
and services provided.  
 Primary care providers not only discussed LARC methods at lower rates than their peers 
in women’s health but in-office availability of these methods was also markedly lower.  Access 
or lack there of to LARC methods has been shown to be a significant barrier for many women 
and when patients are made to see multiple providers in order to access the method they desire, 
they face the potential of an additional financial hardship in the form of multiple co-pays for the 
visits  (Secura et al., 2010).  Furthermore, it was found that women’s health providers were 
significantly more likely to routinely discuss LARC methods with their patients during 
contraceptive counseling indicating that there is a potential practice gap between the 
contraceptive options counseling that would be received by the same woman if she were to visit 
a primary care provider for her contraceptive needs versus a women’s health provider.  It is 
possible that the different approach to discussing LARC methods may stem from the fact that 
primary care providers are less comfortable discussing these methods even though they report 
believing they are safe and believing that their patient populations underutilize them.  From the 
literature, we know that primary care providers are trained in LARC insertion methods at greatly 
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 reduced rates as compared to their counterparts in women’s health (Greenberg et al., 2013; 
Harper et al., 2013).  This difference in specific training may account for some of the data we see 
where primary care providers reported having LARC methods available in their clinics at 
reduced rates compared to their women’s health counterparts.  
 While statistically significant differences were seen almost universally between the 
assessment of MEC understanding for the Cu-IUD between primary care providers and women’s 
health providers, the most concerning differences were the data point as to diabetes, obesity, 
hypertension, and smoking.  Under the CDC MEC, none of these are reasons that would preclude 
a woman from receiving a Cu-IUD and are very common problems addressed in primary care for 
which it would be expected that primary care providers should be aware of the contraception 
options open to these women in order to provide comprehensive counseling.  Additionally, for 
some of these conditions, a Cu-IUD may in fact be the best choice for the woman because recent 
studies have found that OCPs are less effective in obese women and the increased risk of stroke 
is well known for women using OCPs who have hypertension or smoke (Bousser & Kittner, 
2000; Simmons & Edelman, 2016).    
 Additional concerns come about from the differences seen as to provider 
recommendation of LARC methods for adolescents and unmarried women depending on their 
cohabitation status.  For adolescents, an unplanned pregnancy can be catastrophic and have 
lasting impacts that span health outcomes for multiple generations (Guttmacher Institute, 2015; 
Ng & Kaye, 2012).  By providing them with highly effective contraception that has ben endorsed 
as the first-line recommendation by the APA, and therefore reducing their risk of an unintended 
pregnancy, healthcare providers perform a service which has been proven to increase their 
likelihood of finishing high school but also increasing their earning potential for the rest of their 
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life (Ng & Kaye, 2012).  As to the differences in provider recommendations that we saw for 
unmarried cohabitating women versus unmarried women who are not living with their partner, 
there is nothing about these two groups of women, from the information presented to providers, 
that would make one a better candidate for a IUD than the other.  It appears that there may be 
value judgments on the part of the provider that are coming through in their contraceptive 
counseling reccomndations.  These judgments may be entirely unconscious or they may stem 
from the misplaced belief that an unmarried woman who is not cohabitating may have more 
sexual partners than the woman who reports living with a partner and therefore by 
recommending an IUD, the provider would be putting one woman at increased risk for STIs.  
The intrusion of provider bias in contraceptive counseling has the potential to further reduce 
women’s access to LARC methods and may adversely affect women’s relationship with their 
provider if they feel judged by a provider’s actions (Dehlendorf et al., 2014).    
Future Directions 
 From the data collected here, it is clear that continued work to improve LARC access in 
the primary setting.  Such work includes educating primary care providers as to LARC methods 
insertion, appropriate patient selection, and working to reduce the exaggerated concerns as to 
patient co-morbidities on the part of the provider that reduce their likelihood of recommending 
LARC methods.  The best way to do this may be through the use of provider training programs 
as they have been proven to be successful in bringing about demonstrable practice changes in 
providers who have attended (Harper et al., 2015).  Comments left by participants indicated that 
there would be more than adequate attendance at such a program to interest one of the better-
known programs such as “Beyond the Pill” to organize such a training program here.  
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Project Limitations 
One major limitation of the study is its nature as a convenience sample.  While this choice 
was made for logical reasons, it limits the ability of the data to be used to draw conclusions as to 
NP CCP trends on the whole.  Additional problems may lie in having asked providers to report 
about their own practice.  Social desirability bias may have some effect on the data collected, as 
providers would be likely to report behaviors they felt would reflect best on their knowledge 
base and practice trends.  However, if this were to be true, it may make differences in CCP more 
pronounced across the data analysis, which, in the end, may match more closely to the actual 
CCP of providers who fell susceptible to reporting their CCP to match what they believed would 
be socially desirable.  
Furthermore, the survey weighed heavily in its evaluation of provider’s decisions in 
recommending IUD methods based on the CDC MEC.  While questions were asked about the 
ENG-Implant training and provision, questions did not follow the same rigor as placed on those 
evaluating provider knowledge and decision making in regards to the IUD.  In retrospect, it 
would have been very valuable to evaluate provider decision making in the same way as the 
ENG-Implant may be a LARC method that is easier to receive training in, master, and 
subsequently incorporate into practice in the primary care setting than the IUD.  Decisions to 
limit question number were made based on the length of the overall survey and the resulting time 
burden placed on participants and weighed against worries of increased dropout rates among 
participants, which might skew the data collected.  Going forward, it would be worthwhile to 
study provider behaviors specific to the LNG-Implant as it is becoming more and more clear that 
this is the LARC method that might prove easiest for providers to be trained on and subsequently 
provide as an in-office option for long-term contraception in the primary care setting.  
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Conclusions 
 From the data collected, it is clear that we are still in the early stages of adoption of 
LARC methods in the primary care setting.  Despite having been released more than 7 years ago, 
it is clear that providers have not fully embraced and incorporated the first-line contraception 
recommendation changes endorsed by the CDC, ACOG, and AAP.  While some paradigm shifts 
in healthcare occur rapidly, it is clear that this one had a slower trajectory toward full 
incorporation.  Despite that, we remain encouraged by the changes we have seen and the interest 
expressed by participants in learning more about LARC methods.  
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Table 1. Provider Demographics 
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Figure 1. Average number of patients seen per week requiring contraceptive counseling and 
services by provider type. Standard deviations are presented as error bars.  
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Figure 2. Reported time, in minutes, available to providers for contraceptive counseling and 
provider satisfaction with time available by provider type. To determine if differences in 
contraceptive counseling may stem from the amount of time providers have available for a visit, 
providers were asked to estimate the time they have available during an appointment to provide 
contraceptive care and if they were satisfied with the time available and felt that they had 
adequate time available to provide counseling. Reported time available (in minutes) is reflected 
by the bar graph and satisfaction levels by the line graphs.  
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Figure 3. Providers reporting working in clinics where those with prescriptive authority (MD, 
NP, PA) are solely responsible for contraceptive counseling. 
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Figure 4. Provider perception of safety of LARC methods. 
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Figure 5. Provider perception of patient receptiveness to learning about LARC methods during 
contraceptive counseling. 
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Figure 6. Contraceptive methods discussed during contraceptive counseling versus in-clinic 
availability of same methods by provider type. Providers were then asked to indicate all of the 
methods that they discussed, in general, with patients during contraceptive counseling and 
indicate the methods they would have available in office if patient’s were to choose them after 
counseling was finished. Discussion of a method is indicated by the solid lines and availability of 
the same method by dashed lines. Each method is represented by a different color. 
  
  47 
 
 
 
 
Figure 7. Routine discussion of LARC methods during contraceptive counseling by provider 
type. Routine discussion was defined as responses indicating providers discussed these methods 
with either “more than half, but not all” or “all” of their female patients to whom they had 
provided contraceptive counseling. All odds ratios are compared against primary care providers 
having an odds ratio of 1. Statistically significant results are indicated as follows:  
* p=0.00.  
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Figure 8. Effect of selected patient conditions on recommendation of IUD during contraceptive 
counseling by provider type. Respondents were asked about their decision-making during 
contraceptive counseling as part of a well-woman exam (annual physical) or non-acute follow-up 
visit when recommending an IUD for patients with a variety of lifestyle choices or medical 
comorbidities. During analysis, combining responses “no” and “don’t know” as one category 
dichotomized responses. During analysis, provider types were grouped as primary care, FNP, 
AGNP, and PNP, and women’s health, WHNP and CNM. All odds ratios are compared against 
primary care providers having an odds ratio of 1. Statistically significant results are indicated as 
follows: * p=<0.0001; w p=0.0014. 
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Figure 9.  Reported level of provider concern as to selected patient conditions when 
recommending an IUD during contraceptive counseling by provider type. To assess the relative 
impact of these concerns participants were asked to consider a selected set of patient conditions 
and reflect on their relative level of concern for each when considering recommending an IUD. 
For data analysis, responses indicating a moderate or high level of concern might indicate a 
provider are unlikely to recommend an IUD to a patient with the condition in question. All odds 
ratios are compared against women’s health providers having an odds ratio of 1. Statistically 
significant results are indicated as follows: * p=<0.0001; w p=0.0010; ✛ p=0.0113.  
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Figure 10. Effect of provider knowledge of appropriate IUD use for selected patient conditions 
on provider recommendation of the Cu-IUD during contraceptive counseling by provider type.  
Providers were asked a question to assess their understanding of the MEC by asking if they 
would consider recommending a Cu-IUD when certain co-morbidities were present.  During 
analysis, combining responses “no” and “don’t know” as one category dichotomized responses. 
Again, provider types were grouped as primary care, FNP, AGNP, and PNP, and women’s 
health, WHNP and CNM. All odds ratios are compared against primary care providers having an 
odds ratio of 1. Statistically significant results are indicated as follows: * p=<0.0001;  
w p=0.0004.;  ✚ p=0.0494. 
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Figure 11. Expanded graph of the effect of provider knowledge of appropriate IUD use for 
selected patient conditions on provider recommendation of the Cu-IUD during contraceptive 
counseling by provider type. Providers were asked a question to assess their understanding of the 
MEC by asking if they would consider recommending a Cu-IUD when certain co-morbidities 
were present.  During analysis, combining responses “no” and “don’t know” as one category 
dichotomized responses. Again, provider types were grouped as primary care, FNP, AGNP, and 
PNP, and women’s health, WHNP and CNM. All odds ratios are compared against primary care 
providers having an odds ratio of 1. Statistically significant results are indicated as follows:  
* p=<0.0001;  w p=0.0004.  
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Figure 12. Expanded graph of the effect of provider knowledge of appropriate IUD use for 
selected patient conditions on provider recommendation of the Cu-IUD during contraceptive 
counseling by provider type. Providers were asked a question to assess their understanding of the 
MEC by asking if they would consider recommending a Cu-IUD when certain co-morbidities 
were present.  During analysis, combining responses “no” and “don’t know” as one category 
dichotomized responses. Again, provider types were grouped as primary care, FNP, AGNP, and 
PNP, and women’s health, WHNP and CNM. All odds ratios are compared against primary care 
providers having an odds ratio of 1. Statistically significant results are indicated as follows:  
* p=<0.0001; ✚ p=0.0494.  
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APPENDIX A 
Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use (CDC, 2010). 
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APPENDIX B 
Contraceptive Clinical Practice Survey 
You are invited to take part in a survey about contraceptive clinical practice among advanced 
practice registered nurses (APRNs) in North Carolina. This survey is being disseminated as part 
of a research study. Your participation will require approximately 8 minutes. There are no known 
risks or discomforts associated with this survey. Benefits of participating in this include 
furthering understanding of how contraceptive clinical practice varies among practitioners.  
Taking part in this study is completely voluntary. If you choose to be in the study you can 
withdraw at any time without adversely affecting your relationship with anyone at The 
University of North Carolina. Your responses will be kept strictly confidential, and digital data 
will be stored in secure computer files. Any report of this research that is made available to the 
public will not include your name or any other individual information by which you could be 
identified. If you have questions or want a copy or summary of this study’s results, you can 
contact the researcher at the email address below. If you have any questions about whether you 
have been treated in an illegal or unethical way, contact the University of North Carolina 
Institutional Research Board at (919) 966-3113. Please feel free to print a copy of this consent 
page to keep for your records.   
 
Clicking the “Next” button below indicates that you are 18 years of age or older, and indicates 
your consent to participate in this survey.  
  
Thank you for taking part, Emily Ryan, MA, BSN, RN  
The University of North Carolina School of Nursing  
eradford@email.unc.edu 
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1. In the past 12 months, in your current position, have you had at least one occasion to provide 
contraception counseling to your patients? 
m Yes (1) 
m No (2) 
 
Forced Response: If Yes is Selected, Then Skip to Question 2; If No Is Selected, End and Exit 
Survey 
 
 
CURRENT CONTRACEPTIVE CLINICAL PRACTICE 
The following section asks about your current contraceptive clinical practice. It is not meant to 
be an evaluation of your knowledge. Rather, it seeks to identify how practitioners are able to 
provide contraceptive care in real world settings. Therefore, please answer all of the following 
questions from memory to the best of your ability. 
 
2. In a typical week, approximately how many patients do you see for family planning 
services?            
The WHO defines family planning as services that “allow individuals and couples to anticipate 
and attain their desired number of children and the spacing and timing of their births. It is 
achieved through use of contraceptive methods and the treatment of involuntary infertility.” 
(WHO, 2016) 
 
3. For your female patients of reproductive age, ages 15-49, how many need contraception 
counseling, in your opinion? 
m None (1) 
m Some, but less than half (2) 
m About half (3) 
m More than half, but not all (4) 
m All (5) 
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4. Please think about your practice during well woman visits (annual physical) and/or non-acute 
follow up appointments for the following question. With what proportion, do you discuss 
contraception with the following groups? 
 None (1) Some, but less 
than half (2) 
About half 
(3) 
More than 
half, but not 
all (4) 
All (5) 
Women in 
general (1) m  m  m  m  m  
Married 
Women (2) m  m  m  m  m  
Unmarried, 
cohabitating 
women (3) 
m  m  m  m  m  
Unmarried, 
NOT 
cohabitating 
women (4) 
m  m  m  m  m  
Adolescent 
females (age 
15-19) (5) 
m  m  m  m  m  
 
 
5. How much influence do you feel you have on your patients' . . .? 
 None at all 
(1) 
A little (2) A moderate 
amount (3) 
A lot (4) A great deal 
(5) 
CHOICE of 
contraceptive 
method (1) 
m  m  m  m  m  
CORRECT USE 
of contraceptive 
method (2) 
m  m  m  m  m  
CONTINUATION 
with method (3) m  m  m  m  m  
 
 
6. Do you feel you generally have enough time to counsel patients on their contraceptive 
options? 
m Yes (1) 
m No (2) 
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7. During a well woman visit (annual physical) and/or non-acute follow up, approximately how 
much time (in minutes) do you have available to counsel patients on their contraceptive options? 
Please enter a number. 
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8. Who else, without prescriptive authority, in your practice provides contraception counseling to 
patients, if anyone? Check all that apply. 
q RN (1) 
q LPN (2) 
q Social Worker (3) 
q Peer Counselor (4) 
q Other (5) ____________________ 
q No one (6) 
 
9. Which, if any, of these contraceptive methods do you currently discuss with patients during 
contraceptive counseling? Check all that apply. 
q None (1) 
q Male Condoms (2) 
q Female Condoms (3) 
q Diaphragm (4) 
q Oral Contraceptive Pill (OCP) (5) 
q Vaginal Ring (NuvaRing®) (6) 
q Patch (ORTHO EVRA®) (7) 
q Injection (Depo-Provera®) (8) 
q Implant (Nexplanon®) (9) 
q IUD-Copper (Paragard®) (10) 
q IUD-levonorgestril-releasing (Mirena®, Liletta®, Skyla®) (11) 
q Emergency Contraceptive Pill (12) 
 
10. Which, if any, of these contraceptive method services do you currently offer to patients in 
your clinic? Check all that apply. 
q None (1) 
q Diaphragm- provide in clinic fitting (2) 
q Oral Contraceptive Pill (OCP)- samples and/or prescription (3) 
q Vaginal Ring (NuvaRing®) - samples and/or prescription  (4) 
q Patch (ORTHO EVRA®) - samples and/or prescription  (5) 
q Injection (Depo-Provera®) - provide in clinic administration  (6) 
q Implant (Nexplanon®) - provide in clinic insertion  (7) 
q IUD-Copper (Paragard®) - provide in clinic insertion  (8) 
q IUD-levonorgestril-releasing (Mirena®, Liletta® Skyla®) - provide in clinic insertion (9) 
q Emergency Contraceptive Pill - samples and/or prescription  (10) 
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11. In which of these methods, if any, would you like (more) training? Check all that 
apply.  Training would include informational brochures or attending educational programs where 
you would learn about counseling patients in various methods and inserting the long acting, 
reversible (LARC) methods. 
q None (1) 
q Diaphragm (2) 
q Oral Contraceptive Pill (OCP) (3) 
q Vaginal Ring (NuvaRing®) (4) 
q Patch (ORTHO EVRA®) (5) 
q Injection (Depo-Provera®) (6) 
q Implant (Nexplanon®) (7) 
q IUD-Copper (Paragard®) (8) 
q IUD-levonorgestril-releasing (Mirena®, Liletta®, Skyla®) (9) 
q Emergency Contraceptive Pill (10) 
 
12. Among your female patients to whom you have provided contraceptive counseling in the past 
12 months, with how many did you discuss any of the various intrauterine devices (IUDs)-
Paragard®, Mirena®, Liletta®, Skyla® 
m None (1) 
m Some, but less than half (2) 
m About half (3) 
m More than half, but not all (4) 
m All (5) 
 
13. Do you consider the intrauterine devices (IUDs)- Paragard®, Mirena®, Liletta®, Skyla®- to 
be underutilized by your patient population? 
m Yes (1) 
m No (2) 
 
14. Do you consider the intrauterine devices (IUDs)- Paragard®, Mirena®, Liletta®, Skyla®- to 
be safe methods? 
m Yes (1) 
m No (2) 
 
15. Among your female patients, to whom you have provided contraceptive counseling in the 
past 12 months, with how many did you discuss the implant- Nexplanon® 
m None (1) 
m Some, but less than half (2) 
m About half (3) 
m More than half, but not all (4) 
m All (5) 
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16. Do you consider the implant- Nexplanon®- to be underutilized by your patient population? 
m Yes (1) 
m No (2) 
 
17. Do you consider the implant- Nexplanon®- to be a safe method? 
m Yes (1) 
m No (2) 
 
18. During your residency or training did you insert any intrauterine devices (IUDs) -Paragard®, 
Mirena®, Liletta®, or Skyla®?  Residency or training is defined as either a post-graduate NP 
residency and/or clinical rotations or hours performed as part of your educational program. 
m Yes (1) 
m No (2) 
 
19. During your residency or training, did you insert any implants - Nexplanon® or Implanon®?  
Residency or training is defined as either a post-graduate NP residency and/or clinical rotations 
or hours performed as part of your educational program. 
m Yes (1) 
m No (2) 
 
20. Have you sought out post-graduate training to learn how to insert long acting, reversible 
contraception methods (LARCs) including intrauterine devices (IUDs-Paragard®, Mirena®, 
Liletta®, or Skyla®) or implants (Nexplanon® or Implanon®)?     Post graduate training 
includes attending contraceptive technology conferences or manufacturer sponsored educational 
programs where you were taught how to insert and remove these methods.    
m Yes (1) 
m No (2) 
If No Is Selected, Then Skip To Question 22 
 
21. Which type of long acting, reversible contraception methods (LARCs) did you receive post-
graduate training in insertion techniques? Check all that apply. 
q Copper T 380 A (Paragard®) (1) 
q Levonorgestrel-releasing system (Mirena®, Liletta®, or Skyla®) (2) 
q Implant (Nexplanon®) (3) 
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22. Are you comfortable inserting the following methods? 
 Yes (1) Somewhat (2) No (3) 
Copper T 380 A 
(Paragard®) (1) m  m  m  
Levonorgestrel-
releasing system 
(Mirena®, Liletta®, 
or Skyla®) (2) 
m  m  m  
Implant 
(Nexplanon®) (3) m  m  m  
 
 
23. During contraceptive counseling you provide as part of a well woman exam (annual 
physical) or non-acute follow up visit, would you consider recommending an intrauterine device 
(IUD-Paragard®, Mirena®, Liletta®, and/or Skyla®) for the following patients? 
 Yes (1) No (2) Don't Know (3) 
Nulliparous women 
(no births) (1) m  m  m  
Unmarried, 
cohabitating women 
(2) 
m  m  m  
Unmarried, NOT 
cohabitating women 
(3) 
m  m  m  
Immediate post-
partum (prior to 
discharge) (4) 
m  m  m  
Immediate post-
abortion (before 
leaving clinic) (5) 
m  m  m  
History of sexually 
transmitted infections 
(STI) in past 2 years 
(6) 
m  m  m  
History of pelvic 
inflammatory disease 
(PID) (7) 
m  m  m  
History of ectopic 
pregnancy (8) m  m  m  
Adolescent females 
(age 15-19) (9) m  m  m  
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24. How big a concern, if any, is each of the following for you when deciding whether to 
recommend an intrauterine device (IUD-Paragard®, Mirena®, Liletta®, and/or Skyla®) during 
contraceptive counseling? 
 No concern (1) Minor concern 
(2) 
Moderate 
concern (3) 
Major concern 
(4) 
Uterine 
perforation at 
insertion (1) 
m  m  m  m  
Expulsion (2) m  m  m  m  
Sexually 
transmitted 
infections (STI) 
(3) 
m  m  m  m  
Pelvic 
inflammatory 
disease (PID) (4) 
m  m  m  m  
Adolescent age 
(15-19 years) (5) m  m  m  m  
Infertility (6) m  m  m  m  
Changes in 
bleeding pattern 
(7) 
m  m  m  m  
 
 
25. Would you consider the Copper T 380 A (Paragard®) for a patient with . . . ? 
 Yes (1) No (2) Don't Know (3) 
Menorrhagia (1) m  m  m  
Dysmenorrhea (2) m  m  m  
Fibroids (without 
distortion of uterine 
cavity) (3) 
m  m  m  
Diabetes (4) m  m  m  
Obesity (5) m  m  m  
Smoker (6) m  m  m  
History of 
hypertension (7) m  m  m  
Iron deficiency 
anemia (8) m  m  m  
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26. Do you consider cost to the patient when deciding to recommend each of the following 
methods to patients you provide contraceptive counseling? 
 Yes (1) No (2) 
Copper T 380 A (Paragard®) 
(1) m  m  
Levonorgestrel-releasing 
system (Mirena®, Liletta®, or 
Skyla®) (2) 
m  m  
Implant (Nexplanon®) (3) m  m  
 
 
27. In general, do you feel that cost is a prohibitive factor for each of the following methods for 
your patient population? 
 Yes (1) No (2) 
Copper T 380 A (Paragard®) 
(1) m  m  
Levonorgestrel-releasing 
system (Mirena®, Liletta®, or 
Skyla®) (2) 
m  m  
Implant (Nexplanon®) (3) m  m  
 
 
28. Do you think your patients are receptive to learning about intrauterine devices (IUDs-
Paragard®, Mirena®, Liletta®, or Skyla®)? 
m Yes (1) 
m No (2) 
 
29. Do you think your patients are receptive to learning about the implant (Nexplanon®)? 
m Yes (1) 
m No (2) 
 
PROVIDER DEMOGRAPHICS 
The next section asks about your demographic and educational information. 
 
30. What is your gender? 
m Male (1) 
m Female (2) 
m Other, specify (3) ____________________ 
 
31. What is your date of birth (MM/DD/YYYY) 
 
32. What race do you consider yourself? Check all that apply 
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q White (1) 
q Black or African American (2) 
q American Indian or Alaska Native (3) 
q Asian (4) 
q Native Hawaiian or Pacific Islander (5) 
q Other, specify (6) ____________________ 
 
33. Do you consider yourself Hispanic or Latino? 
m Yes (1) 
m No (2) 
 
34. What are your professional qualifications? Check all that apply 
q Family Nurse Practitioner (FNP) (1) 
q Women's Health Nurse Practitioner (WHNP) / Obstetrics & Gynecology Nurse Practitioner 
(OGNP) (2) 
q Adult/Geriatric Nurse Practitioner (AGNP) (3) 
q Pediatric Nurse Practitioner (PNP) (4) 
q Certified Nurse Midwife (CNM) (5) 
 
PATIENT & PRACTICE DEMOGRAPHICS 
The following section asks questions about the demographics of your practice and patient 
population. Please answer these questions as best you can from memory. 
 
35. How would you describe your main clinical practice (where you spend most of the time)? 
q Public Health or Community Clinic (1) 
q Private office or clinic (2) 
q Specialized family planning clinic (funded by federal, state, local, or grant money) (3) 
q University clinic or hospital (4) 
q Private hospital clinic (5) 
q Health Department (6) 
 
36. Where is your practice located? 
m City (1) 
m Suburban community or large town (2) 
m Small town (3) 
m Rural area (4) 
 
37. What is the zip code of your practice location? 
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38. Approximately how many of your patients are . . .? Please give your best estimate. 
 None (1) Some, but 
less than half 
(2) 
About half 
(3) 
More than 
half, but not 
all (4) 
All (5) 
Privately 
Insured (1) m  m  m  m  m  
Recipients of 
Medicaid (2) m  m  m  m  m  
Recipients of 
Medicaid for 
ONLY 
Pregnancy (3) 
m  m  m  m  m  
Recipients of 
Medicaid for 
ONLY 
Family 
Planning (4) 
m  m  m  m  m  
Uninsured (5) m  m  m  m  m  
 
 
39. Approximately how many of your patients are . . .? Please give your best estimate. 
 None (1) Some, but 
less than half 
(2) 
About half 
(3) 
More than 
half, but not 
all (4) 
All (5) 
Adolescent 
females (age 
15-19) (1) 
m  m  m  m  m  
Adult women 
of 
reproductive 
age (20-49) 
(2) 
m  m  m  m  m  
 
 
LARC TRAINING INTEREST 
 
40. At this time would you be interested in attending a post-graduate LARC training program as 
part of a contraceptive clinical practice improvement initiative? 
m Yes (1) 
m No (2) 
 
41. Please provide any additional comments you have and would like to add to the survey below. 
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